Next Article in Journal
Relaxation Dynamics of Chlorophyll b in the Sub-ps Ultrafast Timescale Measured by 2D Electronic Spectroscopy
Previous Article in Journal
Para-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
IJMS
Volume 21
Issue 8
10.3390/ijms21082839
ijms-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Review

COVID-19 Drug Discovery Using Intensive Approaches

by
Ayumu Asai
1,2,3,4,
Masamitsu Konno
1,
Miyuki Ozaki
1,
Chihiro Otsuka
1,
Andrea Vecchione
5,
Takahiro Arai
1,6,
Toru Kitagawa
1,3,7,
Ken Ofusa
1,8,
Masami Yabumoto
1,9,
Takaaki Hirotsu
1,10,
Masateru Taniguchi
2,
Hidetoshi Eguchi
1,3,
Yuichiro Doki
1,3 and
Hideshi Ishii
1,*
1
Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan
2
Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
3
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
4
Artificial Intelligence Research Center, Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
5
Department of Clinical and Molecular Medicine, University of Rome “Sapienza”, Santo Andrea Hospital, via di Grottarossa, 1035-00189 Rome, Italy
6
Unitech Co., Ltd., Kashiwa 277-0005, Japan
7
Kyowa-kai Medical Corporation, Osaka 540-0008, Japan
8
Prophoenix Division, Food and Life-Science Laboratory, Idea Consultants, Inc., Osaka-City, Osaka 559-8519, Japan
9
Kinshu-Kai Medical Corporation, Osaka 558-0041, Japan
10
Hirotsu Bio Science Inc., Tokyo 107-0062, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(8), 2839; https://doi.org/10.3390/ijms21082839
Received: 27 March 2020 / Revised: 9 April 2020 / Accepted: 14 April 2020 / Published: 18 April 2020
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
View Full-Text Download PDF
Browse Figure

Abstract

Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. View Full-Text
Keywords: COVID-19; coronavirus; infection; drug discovery; drug repositioning COVID-19; coronavirus; infection; drug discovery; drug repositioning
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
SciFeed

Share and Cite

MDPI and ACS Style

Asai, A.; Konno, M.; Ozaki, M.; Otsuka, C.; Vecchione, A.; Arai, T.; Kitagawa, T.; Ofusa, K.; Yabumoto, M.; Hirotsu, T.; Taniguchi, M.; Eguchi, H.; Doki, Y.; Ishii, H. COVID-19 Drug Discovery Using Intensive Approaches. Int. J. Mol. Sci. 2020, 21, 2839. https://doi.org/10.3390/ijms21082839

AMA Style

Asai A, Konno M, Ozaki M, Otsuka C, Vecchione A, Arai T, Kitagawa T, Ofusa K, Yabumoto M, Hirotsu T, Taniguchi M, Eguchi H, Doki Y, Ishii H. COVID-19 Drug Discovery Using Intensive Approaches. International Journal of Molecular Sciences. 2020; 21(8):2839. https://doi.org/10.3390/ijms21082839

Chicago/Turabian Style

Asai, Ayumu, Masamitsu Konno, Miyuki Ozaki, Chihiro Otsuka, Andrea Vecchione, Takahiro Arai, Toru Kitagawa, Ken Ofusa, Masami Yabumoto, Takaaki Hirotsu, Masateru Taniguchi, Hidetoshi Eguchi, Yuichiro Doki, and Hideshi Ishii. 2020. "COVID-19 Drug Discovery Using Intensive Approaches" International Journal of Molecular Sciences 21, no. 8: 2839. https://doi.org/10.3390/ijms21082839

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop